All News
Improving Cardiovascular Trends in Rheumatoid Arthritis
Myasoedova and colleagues from the Mayo Clinic have reported their new data that demonstrates improving cardiovascular (CV) mortality rates in current RA patients treated with modern drugs.
Read Article
2015 ACR RA Guidelines Released– Finally!
ACR 2015 RA treatment guidelines were published yesterday, nearly a year after they were preliminarily presented at the 2014 ACR meeting in Boston. After a year of review and revision these have been posted.
Read Article
Biosimilars and the FDA
Biosimilars are in the news and will be prominently on parade at next week's ACR meeting in San Francisco. Biosimilars are similar to, but not the same as, innovator biologics.
Read Article
Economic Burden of ANCA-Associated Vasculitis in the USA
To assess the prevalence and magnitude of healthcare costs associated with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in the USA, researchers analyzed adminstrative data from Truven Health MarketScan Commercial and Medicare Supplemental databases.
Read Article
Repeat Skin Cancer Risk with Methotrexate and Biologics
Using Medicare claims data, a retrospective cohort study analyzed the risk of a second non-melanomatous skin cancer (NMSC) in 9460 individuals (6841 with RA and 2788 with IBD).
Read Article
High Level Skin Responses Seen with Inhibitor of IL-23p19 in Psoriasis
Rheumatology News reports the results of a novel trial presented at the European Academy of Dermatology and Venereology meeting in Copenhagen.
Read Article
FDA Panel Votes 10-4 to Approve Lesinurad for the Treatment of Hyperuricemia/Gout
Despite concerns over safety, the FDA Arthritis Advisory Committee voted favorably to approve lesinurad (LES) at a meeting held Friday, October 23, 2015. Overall, panel members felt the potential benefits of LES outweighed the safety concerns reviewed by the FDA presenters.
Read Article
FDA Holds Off on Xeljanz Approval for Psoriasis
The FDA has denied Pfizer's application seeking an indication for Xeljanz in patients with moderate to severe chronic plaque psoriasis.
Read Article
Circadian Efficacy with Cathepsin K Inhibitor ONO-5334
Osteoporosis is associated with significant morbidity, and hip fractures as sequelae confer a 1-year mortality risk of 8.4–36%.
Read Article
Brodalumab vs. Ustekinumab: Head-to-Head Studies of Psoriasis
AMAGINE-2 and AMAGINE-3 are in two phase 3 studies that compare multiple doses of brodalumab (anti-IL-17) and ustekinumab (anti-12/23) in adults with moderate-to-severe psoriasis.
Read Article
Ustekinumab Effective in Adolescents with Psoriasis
Biologic and new drug development seldom targets children and adolescents. This study evaluated the efficacy and safety of ustekinumab in adolescents age 12 to 17 years with moderate-to-severe psoriasis,
Read Article
Secukinumab Wins in Psoriatic Arthritis
Mease and colleagues have published their results of a phase 3 trial of secukinumab (anti-IL-17A Mab) in 606 patients with psoriatic arthritis (PsA).
Read Article
ACR/SPARTAN 2015 Recommendations for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
The ACR and SPARTAN (Spondyloarthritis Research and Treatment Network) has worked together to study 57 specific treatment questions regarding AS and SpA. The following guidelines have recently been published after conducting systematic literature reviews.
Read Article
Dr. Woodcock Gives Senate FDA Update on Biosimilars
Biologics have been a great advance in therapeutics, but at great cost. Although biologics account for less than 1% of all prescriptions in the USA, they account for 28% percent of the cost of prescribed medications.
Read Article
Biosimilar SB4 Performs Equally to Etanercept
Biosimilars are rapidly growing. Many of these will have their first introduction to countries outside of the USA. There is concern whether biosimilars will provide identical pharmacodynamics, biological function, efficacy and toxicity to reference products, both in the short and long term.
Read Article
PLLR - The Pregnancy & Lactation Labeling Rule Explained
A recent article from Healio.com reviewed the FDA’s Pregnancy and Lactation Labeling Rule (PLLR) that became effective June 30th.
Read Article
DATA-Switch Study Finds the Right Sequence to Building Better Bone Mass
Long-term management of osteoporosis can be challenging, and given the increasing number of choices, the best sequence of drug use has not been addressed adequately.
Read Article
Future 2 Trial Shows Secukinumab Efficacy in Psoriatic Arthritis
Secukinumab (Cosentyx) is an anti-IL-17 monoclonal antibody currently approved for use in moderate to severe psoriasis. It has also been studied in psoriatic arthritis (PsA) and shown to be safe and effective.
Read Article
DAS28-CRP or DAS28-ESR: Are they Biosimilar?
The disease activity score (DAS28) has been developed as a dynamic assessment tool and a therapeutic response measure for use in clinical trials and practice.
Read Article
Gouty Tomatoes, Alveolar Hemorrhage and Famous RA Faces: August 2015 Top Social Media News
In August, RheumNow published 76 tweets covering novel news, research and teaching points gleaned from the medical literature, regulatory reports and internet sources. We had a reach (impressions) of 60,800, with 45 mentions, and 2049 visits to RheumNow.com.
Read Article
